Daina Andersone
Pauls Stradiņš Clinical University Hospital(LV)University of Latvia(LV)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study(2009)469 cited
- → Physical inactivity in patients with rheumatoid arthritis: Data from twenty‐one countries in a cross‐sectional, international study(2007)355 cited
- → Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study(2010)284 cited
- → Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity(2011)180 cited
- → Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study(2016)137 cited
- → Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial(2019)27 cited
- → EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries(2020)18 cited
- → Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries(2019)12 cited
- → Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients(2020)9 cited
- → Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study(2017)2 cited